Latest Industry Insights

Fluid Imaging Technologies and the University of Colorado Boulder have recently entered an exclusive research agreement to determine whether the University’s artificial intelligence software can identify bloodborne bacteria. We spoke with Kent Peterson, CEO, Fluid Imaging Technologies, to learn more about the collaboration, the technologies involved, and how they could impact patients.

Given the brain's complexity, it's no surprise that deep neural networks (DNN), computing system based on the brain, are challenging to design and improve. That is a challenge that companies like DarwinAI are meeting head-on. We talked to Sheldon Fernandez, DarwinAI’s CEO, to find out more.

We recently spoke with Luca Quagliata, Ph.D., Global Director of Medical Affairs for Thermo Fisher Scientific. Previously, Quagliata was involved in one of the first teams in Europe to introduce Next Generation Sequencing (NGS) in routine molecular diagnostics. Here, he shares his perspectives on the field, particularly the use of NGS in the analysis of liquid biopsies, the discovery of cancer biomarkers and the potential application of artificial intelligence (AI) in molecular diagnostics.

FAIR is a set of data principles that hopes to form a gold standard for scientific data management. Non-profit the Pistoia Alliance has developed a toolkit to help companies adopt FAIR. We spoke to Pistoia's Ian Harrow to find out more.

Data has been called the crucial raw material of the 21st century. As such, materials companies are waking up to the importance of having an informatics strategy. We caught up with Lux Research's Xiao Zhong, Ph.D., who recently authored a report explaining the key steps in creating a materials informatics strategy, to find out more.

Robotic and automation technologies are advancing at a staggering rate, and the introduction of collaborative robots has fundamentally changed the way scientists coexist with automated systems.. Ira Hoffman, CEO at HighRes Biosolutions® tells us about the company’s mission to “improve human health through life science robotics”.

The pipeline to new drugs isn’t straightforward, but pharmas can pool their data resources to speed things up. The MELLODDY consortium hopes to make data sharing simple and secure. We talked to Hugo Ceulemans, MELLODDY Project Leader and Mathieu Galtier, Project Coordinator at Owkin to find out more.

Imagine if there was a better way to write, format, and review scientific manuscripts for publication. doDOC Document Collaboration Expert Leif Måsvær believes there is. Leif explains how this cloud-based platform is a game-changer that overcomes the major obstacles present during the authoring, writing, and reviewing process.

Whilst some aspects of biochemistry research have become increasingly high-throughput, other, like analysis of chemical data, are too often laborious and slow. We talked to Andrew Anderson, Vice President of Innovation and Informatics Strategy at ACD/Labs about how the field is being changed by automation and how Katalyst hopes to speed up pharmaceutical development.

The pharmaceutical and biotechnology industry is the number one target for cybercriminals, according to recent survey. Unsurprisingly, data security is now top of the agenda for most companies in this sector. How can organizations balance robust cybersecurity with the need for efficient flow of information between colleagues and collaborators?